You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTrimipramine
Accession NumberDB00726  (APRD00498)
TypeSmall Molecule
GroupsApproved
Description

Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. [PubChem]

Structure
Thumb
Synonyms
10,11-dihydro-N,N,beta-Trimethyl-5H-dibenz[b,F]azepine-5-propanamine
5-(gamma-dimethylamino-beta-Methylpropyl)-10,11-dihydro-5H-dibenzo[b,F]azepine
5-[3-(dimethylamino)-2-Methylpropyl]-10,11-dihydro-5H-dibenz[b,F]azepine
beta-Methylimipramine
RP-7162
Sapilent
Trimeprimina
Trimeprimine
Trimeproprimine
Trimipramina
Trimipramine
Trimipraminum
External Identifiers
  • IF 6120
  • IL 6001
  • RP 7162
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Novo-tripramine Tab 100mg BPtablet100 mgoralNovopharm Limited1991-12-312015-10-26Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Novo-tripramine Tab 25mg BPtablet25 mgoralNovopharm Limited1991-12-312015-10-26Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Novo-tripramine Tab 50mg BPtablet50 mgoralNovopharm Limited1991-12-312015-10-26Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Nu-trimipramine Tab 100mgtablet100 mgoralNu Pharm Inc1993-12-312012-09-04Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Nu-trimipramine Tab 12.5mgtablet12.5 mgoralNu Pharm Inc1993-12-312012-09-04Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Nu-trimipramine Tab 25mgtablet25 mgoralNu Pharm Inc1993-12-312012-09-04Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Nu-trimipramine Tab 50mgtablet50 mgoralNu Pharm Inc1993-12-312012-09-04Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Rhotriminetablet50 mgoralSanofi Aventis Canada Inc1988-12-312006-07-28Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Rhotriminetablet25 mgoralSanofi Aventis Canada Inc1988-12-312006-07-28Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Rhotriminetablet12.5 mgoralSanofi Aventis Canada Inc1988-12-312006-07-28Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Rhotriminecapsule75 mgoralSanofi Aventis Canada Inc1988-12-312007-03-29Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Rhotriminetablet100 mgoralSanofi Aventis Canada Inc1988-12-312007-03-29Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Surmontilcapsule25 mg/1oralTeva Women's Health, Inc.1990-09-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Surmontiltablet25 mgoralSanofi Aventis Canada Inc1964-12-312006-07-28Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Surmontilcapsule100 mg/1oralTeva Women's Health, Inc.1990-09-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Surmontiltablet50 mgoralSanofi Aventis Canada Inc1971-12-312006-07-28Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Surmontilcapsule50 mg/1oralTeva Women's Health, Inc.1990-09-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Surmontil 100tablet100 mgoralAventis Pharma Inc1964-12-312005-08-01Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Surmontil 12.5tablet12.5 mgoralAventis Pharma Inc1968-12-312005-08-01Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Surmontil 75capsule75 mgoralAventis Pharma Inc1979-12-312005-08-01Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Trimipraminetablet100 mgoralAa Pharma Inc1987-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Trimipraminetablet50 mgoralAa Pharma Inc1987-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Trimipraminetablet25 mgoralAa Pharma Inc1987-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Trimipraminetablet12.5 mgoralAa Pharma Inc1987-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Trimipraminecapsule75 mgoralAa Pharma Inc1994-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Trimipramine Tab 100mgtablet100 mgoralPro Doc Limitee1987-12-312010-07-13Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Trimipramine Tab 12.5mgtablet12.5 mgoralPro Doc Limitee1987-12-312009-07-23Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Trimipramine Tab 25mgtablet25 mgoralPro Doc Limitee1987-12-312010-07-13Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Trimipramine Tab 50mgtablet50 mgoralPro Doc Limitee1987-12-312010-07-13Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Trimipramine-75 - Cap 75mgcapsule75 mgoralPro Doc Limitee1995-12-312010-07-13Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-trimipraminecapsule75 mgoralApotex IncNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Apo-trimipraminetablet100 mgoralApotex IncNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Apo-trimipraminetablet50 mgoralApotex IncNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Apo-trimipraminetablet25 mgoralApotex IncNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Apo-trimipraminetablet12.5 mgoralApotex IncNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Trimipramine Maleatecapsule25 mg/1oralActavis Pharma, Inc.2011-11-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Trimipramine Maleatecapsule100 mg/1oralActavis Pharma, Inc.2011-10-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Trimipramine Maleatecapsule50 mg/1oralActavis Pharma, Inc.2011-11-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Over the Counter ProductsNot Available
International Brands
NameCompany
HerphonalTemmler
SapilentExtractumPharma
StangylSanofi-Aventis
TrimiduraMylan dura
TrimineurinHexal
TripressMylan
TydamineAspen Pharmacare
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Trimipramine maleate
ThumbNot applicableDBSALT000969
Categories
CAS number739-71-9
WeightAverage: 294.4338
Monoisotopic: 294.209598842
Chemical FormulaC20H26N2
InChI KeyInChIKey=ZSCDBOWYZJWBIY-UHFFFAOYSA-N
InChI
InChI=1S/C20H26N2/c1-16(14-21(2)3)15-22-19-10-6-4-8-17(19)12-13-18-9-5-7-11-20(18)22/h4-11,16H,12-15H2,1-3H3
IUPAC Name
(3-{2-azatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,11,13-hexaen-2-yl}-2-methylpropyl)dimethylamine
SMILES
CC(CN(C)C)CN1C2=CC=CC=C2CCC2=CC=CC=C12
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dibenzazepines. These are compounds with two benzene rings connected by an azepine ring. Azepine is an unsaturated seven-member heterocycle with one nitrogen atom replacing a carbon atom.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzazepines
Sub ClassDibenzazepines
Direct ParentDibenzazepines
Alternative Parents
Substituents
  • Dibenzazepine
  • Alkyldiarylamine
  • Azepine
  • Benzenoid
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of depression and depression accompanied by anxiety, agitation or sleep disturbance
PharmacodynamicsTrimipramine is a tricyclic antidepressant. It was thought that tricyclic antidepressants work by inhibiting the re-uptake of the neurotransmitters norepinephrine and serotonin by nerve cells. However, this response occurs immediately, yet mood does not lift for around two weeks. It is now thought that changes occur in receptor sensitivity in the cerebral cortex and hippocampus. The hippocampus is part of the limbic system, a part of the brain involved in emotions. Presynaptic receptors are affected: a1 and b1 receptors are sensitized, a2 receptors are desensitised (leading to increased noradrenaline production). Tricyclics are also known as effective analgesics for different types of pain, especially neuropathic or neuralgic pain. A precise mechanism for their analgesic action is unknown, but it is thought that they modulate anti-pain opioid systems in the CNS via an indirect serotonergic route. They are also effective in migraine prophylaxis, but not in abortion of acute migraine attack. The mechanism of their anti-migraine action is also thought to be serotonergic.
Mechanism of actionTrimipramine's mechanism of action differs from other tricyclic antidepressants. Trimipramine acts by decreasing the reuptake of norepinephrine and serotonin (5-HT).
AbsorptionRapid absorption
Volume of distributionNot Available
Protein binding93%-96% (to plasma proteins)
Metabolism

Hepatic

Route of eliminationNot Available
Half life11-18 hrs
ClearanceNot Available
ToxicitySide effects include agitation, coma, confusion, convulsions, dilated pupils, disturbed concentration, drowsiness, hallucinations, high fever, irregular heart rate, low body temperature, muscle rigidity, overactive reflexes, severely low blood pressure, stupor, vomiting
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9739
Blood Brain Barrier+0.9861
Caco-2 permeable+0.8059
P-glycoprotein substrateSubstrate0.6559
P-glycoprotein inhibitor IInhibitor0.8838
P-glycoprotein inhibitor IIInhibitor0.8826
Renal organic cation transporterInhibitor0.7098
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.6698
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9094
CYP450 3A4 inhibitorNon-inhibitor0.6132
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6083
Ames testNon AMES toxic0.8109
CarcinogenicityNon-carcinogens0.9021
BiodegradationNot ready biodegradable0.9886
Rat acute toxicity2.8709 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9065
hERG inhibition (predictor II)Inhibitor0.8271
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Capsuleoral75 mg
Tabletoral100 mg
Tabletoral12.5 mg
Tabletoral25 mg
Tabletoral50 mg
Capsuleoral100 mg/1
Capsuleoral25 mg/1
Capsuleoral50 mg/1
Prices
Unit descriptionCostUnit
Trimipramine maleate powder51.0USD g
Surmontil 100 mg capsule5.92USD capsule
Surmontil 50 mg capsule4.15USD capsule
Trimipramine Maleate 50 mg capsule3.27USD capsule
Trimipramine 50 mg capsule3.14USD capsule
Surmontil 25 mg capsule2.49USD capsule
Trimipramine 25 mg capsule1.92USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point45 °CPhysProp
water solubilitySlightly solubleNot Available
logP4.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.026 mg/mLALOGPS
logP4.67ALOGPS
logP4.76ChemAxon
logS-4ALOGPS
pKa (Strongest Basic)9.42ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area6.48 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity95.02 m3·mol-1ChemAxon
Polarizability35.67 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
MSMass Spectrum (Electron Ionization)splash10-nsz0000000-53c724efbeeb45818f39View in MoNA
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesN06AA06
AHFS Codes
  • 28:16.04.28
PDB EntriesNot Available
FDA labelDownload (152 KB)
MSDSDownload (75 KB)
Interactions
Drug Interactions
Drug
AbirateroneThe serum concentration of Trimipramine can be increased when it is combined with Abiraterone.
AcepromazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Acepromazine.
AcetophenazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Acetophenazine.
Acetylsalicylic acidTrimipramine may increase the antiplatelet activities of Acetylsalicylic acid.
AclidiniumAclidinium may increase the anticholinergic activities of Trimipramine.
AltretamineAltretamine may increase the orthostatic hypotensive activities of Trimipramine.
AmisulprideThe risk or severity of adverse effects can be increased when Trimipramine is combined with Amisulpride.
AmphetamineTrimipramine may increase the stimulatory activities of Amphetamine.
AprepitantThe serum concentration of Trimipramine can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Trimipramine is combined with Aripiprazole.
AzelastineTrimipramine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Trimipramine.
BatimastatThe serum concentration of Trimipramine can be increased when it is combined with Batimastat.
BenzquinamideThe risk or severity of adverse effects can be increased when Trimipramine is combined with Benzquinamide.
BexaroteneThe serum concentration of Trimipramine can be decreased when it is combined with Bexarotene.
BortezomibThe metabolism of Trimipramine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Trimipramine can be decreased when it is combined with Bosentan.
Botulinum Toxin Type ATrimipramine may increase the anticholinergic activities of Botulinum Toxin Type A.
Botulinum Toxin Type BTrimipramine may increase the anticholinergic activities of Botulinum Toxin Type B.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.
BuprenorphineTrimipramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
BupropionThe metabolism of Trimipramine can be decreased when combined with Bupropion.
ButabarbitalThe metabolism of Trimipramine can be increased when combined with Butabarbital.
ButethalThe metabolism of Trimipramine can be increased when combined with Butethal.
CarphenazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Carphenazine.
CathinoneTrimipramine may increase the stimulatory activities of Cathinone.
ChlormezanoneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Chlormezanone.
ChlorpromazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Chlorpromazine.
ChlorpropamideTrimipramine may increase the hypoglycemic activities of Chlorpropamide.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Chlorprothixene.
CimetidineThe metabolism of Trimipramine can be decreased when combined with Cimetidine.
Cimetropium BromideTrimipramine may increase the anticholinergic activities of Cimetropium Bromide.
CinacalcetThe serum concentration of Trimipramine can be increased when it is combined with Cinacalcet.
CitalopramThe risk or severity of adverse effects can be increased when Trimipramine is combined with Citalopram.
ClozapineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Clozapine.
ConivaptanThe serum concentration of Trimipramine can be increased when it is combined with Conivaptan.
DabrafenibThe serum concentration of Trimipramine can be decreased when it is combined with Dabrafenib.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Trimipramine.
DasatinibThe serum concentration of Trimipramine can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Trimipramine can be decreased when it is combined with Deferasirox.
DesmopressinThe risk or severity of adverse effects can be increased when Trimipramine is combined with Desmopressin.
DexmethylphenidateThe risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Trimipramine.
DicoumarolTrimipramine may increase the anticoagulant activities of Dicoumarol.
DipivefrinThe therapeutic efficacy of Dipivefrin can be decreased when used in combination with Trimipramine.
DofetilideTrimipramine may increase the QTc-prolonging activities of Dofetilide.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.
DuloxetineDuloxetine may increase the serotonergic activities of Trimipramine.
EluxadolineTrimipramine may increase the activities of Eluxadoline.
EscitalopramThe risk or severity of adverse effects can be increased when Trimipramine is combined with Escitalopram.
EthanolTrimipramine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
FencamfamineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Fencamfamine.
FluconazoleThe metabolism of Trimipramine can be decreased when combined with Fluconazole.
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Trimipramine.
FlupentixolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Fluphenazine.
FluspirileneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Fluspirilene.
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Trimipramine.
FosaprepitantThe serum concentration of Trimipramine can be increased when it is combined with Fosaprepitant.
Fusidic AcidThe serum concentration of Trimipramine can be increased when it is combined with Fusidic Acid.
Glucagon recombinantThe risk or severity of adverse effects can be increased when Trimipramine is combined with Glucagon recombinant.
GoserelinTrimipramine may increase the QTc-prolonging activities of Goserelin.
GranisetronGranisetron may increase the serotonergic activities of Trimipramine.
HaloperidolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Haloperidol.
HeptabarbitalThe metabolism of Trimipramine can be increased when combined with Heptabarbital.
HexobarbitalThe metabolism of Trimipramine can be increased when combined with Hexobarbital.
HydrocodoneTrimipramine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.
IcosapentTrimipramine may increase the antiplatelet activities of Icosapent.
IdelalisibThe serum concentration of Trimipramine can be increased when it is combined with Idelalisib.
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Trimipramine.
Ipratropium bromideIpratropium bromide may increase the anticholinergic activities of Trimipramine.
IsoflurophateThe serum concentration of Trimipramine can be increased when it is combined with Isoflurophate.
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Trimipramine.
IvacaftorThe serum concentration of Trimipramine can be increased when it is combined with Ivacaftor.
LeuprolideTrimipramine may increase the QTc-prolonging activities of Leuprolide.
LinezolidLinezolid may increase the serotonergic activities of Trimipramine.
LiothyronineLiothyronine may increase the arrhythmogenic activities of Trimipramine.
LithiumLithium may increase the neurotoxic activities of Trimipramine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Trimipramine.
LoxapineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Loxapine.
LuliconazoleThe serum concentration of Trimipramine can be increased when it is combined with Luliconazole.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.
MesoridazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Mesoridazine.
MethohexitalThe metabolism of Trimipramine can be increased when combined with Methohexital.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Methotrimeprazine.
Methylene blueTrimipramine may increase the serotonergic activities of Methylene blue.
MethylphenidateThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Trimipramine.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Trimipramine.
MetyrosineTrimipramine may increase the sedative activities of Metyrosine.
MianserinMianserin may increase the anticholinergic activities of Trimipramine.
MidodrineTrimipramine may increase the activities of Midodrine.
MifepristoneThe serum concentration of Trimipramine can be increased when it is combined with Mifepristone.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.
MirabegronThe risk or severity of adverse effects can be increased when Trimipramine is combined with Mirabegron.
MitotaneThe serum concentration of Trimipramine can be decreased when it is combined with Mitotane.
MolindoneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Morphine.
MoxonidineThe therapeutic efficacy of Moxonidine can be decreased when used in combination with Trimipramine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.
NelfinavirThe metabolism of Trimipramine can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Trimipramine can be increased when it is combined with Netupitant.
NicorandilTrimipramine may increase the hypotensive activities of Nicorandil.
OlanzapineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Olanzapine.
OndansetronThe risk or severity of adverse effects can be increased when Trimipramine is combined with Ondansetron.
OrciprenalineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Orciprenaline.
OrphenadrineTrimipramine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
PalbociclibThe serum concentration of Trimipramine can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Paliperidone.
PanobinostatThe serum concentration of Trimipramine can be increased when it is combined with Panobinostat.
ParaldehydeTrimipramine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Trimipramine.
Peginterferon alfa-2bThe serum concentration of Trimipramine can be decreased when it is combined with Peginterferon alfa-2b.
PentobarbitalThe metabolism of Trimipramine can be increased when combined with Pentobarbital.
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.
PerphenazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Perphenazine.
PhenelzinePhenelzine may increase the serotonergic activities of Trimipramine.
PhenytoinThe metabolism of Trimipramine can be increased when combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Trimipramine is combined with Pimozide.
PiperacetazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Piperacetazine.
Potassium ChlorideTrimipramine may increase the ulcerogenic activities of Potassium Chloride.
PramipexoleTrimipramine may increase the sedative activities of Pramipexole.
PramlintidePramlintide may increase the anticholinergic activities of Trimipramine.
PrimidoneThe metabolism of Trimipramine can be increased when combined with Primidone.
ProchlorperazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Prochlorperazine.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Trimipramine.
PromazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Promazine.
QuetiapineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Quetiapine.
QuinidineTrimipramine may increase the QTc-prolonging activities of Quinidine.
RamosetronTrimipramine may increase the activities of Ramosetron.
RemoxiprideThe risk or severity of adverse effects can be increased when Trimipramine is combined with Remoxipride.
ReserpineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Reserpine.
RisperidoneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Risperidone.
RitonavirThe metabolism of Trimipramine can be decreased when combined with Ritonavir.
RopiniroleTrimipramine may increase the sedative activities of Ropinirole.
RotigotineTrimipramine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Trimipramine.
SecobarbitalThe metabolism of Trimipramine can be increased when combined with Secobarbital.
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Trimipramine.
SertindoleThe risk or severity of adverse effects can be increased when Trimipramine is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Trimipramine.
SiltuximabThe serum concentration of Trimipramine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Trimipramine can be increased when it is combined with Simeprevir.
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.
St. John's WortThe metabolism of Trimipramine can be increased when combined with St. John's Wort.
StiripentolThe serum concentration of Trimipramine can be increased when it is combined with Stiripentol.
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Trimipramine.
SuvorexantTrimipramine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
TacrineThe therapeutic efficacy of Trimipramine can be decreased when used in combination with Tacrine.
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Trimipramine.
TerbinafineThe metabolism of Trimipramine can be decreased when combined with Terbinafine.
ThalidomideTrimipramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThioridazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Thiothixene.
TiclopidineThe metabolism of Trimipramine can be decreased when combined with Ticlopidine.
TiotropiumTrimipramine may increase the anticholinergic activities of Tiotropium.
TocilizumabThe serum concentration of Trimipramine can be decreased when it is combined with Tocilizumab.
TopiramateThe risk or severity of adverse effects can be increased when Trimipramine is combined with Topiramate.
TramadolTrimipramine may increase the neuroexcitatory activities of Tramadol.
TranylcypromineTranylcypromine may increase the serotonergic activities of Trimipramine.
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Trimipramine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Triflupromazine.
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Trimipramine.
Valproic AcidThe serum concentration of Trimipramine can be increased when it is combined with Valproic Acid.
YohimbineThe serum concentration of Yohimbine can be increased when it is combined with Trimipramine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Ziprasidone.
ZolpidemTrimipramine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

1. Sodium-dependent serotonin transporter

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
Sodium-dependent serotonin transporter P31645 Details

References:

  1. Diamond M, Kelly JP, Connor TJ: Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur Neuropsychopharmacol. 2006 Oct;16(7):481-90. Epub 2006 Jan 4. Pubmed
  2. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. Pubmed

2. Sodium-dependent noradrenaline transporter

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
Sodium-dependent noradrenaline transporter P23975 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

3. Sodium-dependent dopamine transporter

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Sodium-dependent dopamine transporter Q01959 Details

References:

  1. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. Pubmed

4. 5-hydroxytryptamine receptor 2A

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: agonist

Components

Name UniProt ID Details
5-hydroxytryptamine receptor 2A P28223 Details

References:

  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. Pubmed

5. 5-hydroxytryptamine receptor 1A

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
5-hydroxytryptamine receptor 1A P08908 Details

References:

  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. Pubmed

6. Alpha-1A adrenergic receptor

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
Alpha-1A adrenergic receptor P35348 Details

References:

  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. Pubmed

7. Alpha-1B adrenergic receptor

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
Alpha-1B adrenergic receptor P35368 Details

References:

  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. Pubmed

8. D(2) dopamine receptor

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: other/unknown

Components

Name UniProt ID Details
D(2) dopamine receptor P14416 Details

References:

  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. Pubmed

9. Alpha-2B adrenergic receptor

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: other/unknown

Components

Name UniProt ID Details
Alpha-2B adrenergic receptor P18089 Details

References:

  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. Pubmed

10. Histamine H1 receptor

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
Histamine H1 receptor P35367 Details

References:

  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. Pubmed

11. 5-hydroxytryptamine receptor 2C

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
5-hydroxytryptamine receptor 2C P28335 Details

References:

  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. Pubmed
  2. TTD
  3. Roth, BL; Driscol, J (12 January 2011). “PDSP Ki Database”. Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Retrieved 30 November 2013.

12. 5-hydroxytryptamine receptor 3A

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: binder

Components

Name UniProt ID Details
5-hydroxytryptamine receptor 3A P46098 Details

References:

  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. Pubmed

13. 5-hydroxytryptamine receptor 1D

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: binder

Components

Name UniProt ID Details
5-hydroxytryptamine receptor 1D P28221 Details

References:

  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. Pubmed

14. Alpha-2A adrenergic receptor

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: desensitize the target

Components

Name UniProt ID Details
Alpha-2A adrenergic receptor P08913 Details

References:

  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. Pubmed

15. D(1) dopamine receptor

Kind: Protein group

Organism: Human

Pharmacological action: unknown

Actions: binder

Components

Name UniProt ID Details
D(1A) dopamine receptor P21728 Details
D(1B) dopamine receptor P21918 Details

References:

  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. Pubmed

16. Beta adrenergic receptor

Kind: Protein group

Organism: Human

Pharmacological action: unknown

Actions: binder

Components

Name UniProt ID Details
Beta-1 adrenergic receptor P08588 Details
Beta-2 adrenergic receptor P07550 Details
Beta-3 adrenergic receptor P13945 Details

References:

  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. Pubmed

17. Muscarinic acetylcholine receptor

Kind: Protein group

Organism: Human

Pharmacological action: unknown

Actions: binder

Components

Name UniProt ID Details
Muscarinic acetylcholine receptor M1 P11229 Details
Muscarinic acetylcholine receptor M2 P08172 Details
Muscarinic acetylcholine receptor M3 P20309 Details
Muscarinic acetylcholine receptor M4 P08173 Details
Muscarinic acetylcholine receptor M5 P08912 Details

References:

  1. Eikmeier G, Muszynski K, Berger M, Gastpar M: High-dose trimipramine in acute schizophrenia. Preliminary results of an open trial. Pharmacopsychiatry. 1990 Sep;23(5):212-4. Pubmed

18. 5-hydroxytryptamine receptor 1C

Kind: Protein

Organism: Rat

Pharmacological action: unknown

Actions: binder

Components

Name UniProt ID Details
5-hydroxytryptamine receptor 2C P08909 Details

References:

  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. Pubmed

Enzymes

1. Cytochrome P450 2D6

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2D6 P10635 Details

References:

  1. Baumann P: Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996 Dec;31(6):444-69. Pubmed
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

2. Cytochrome P450 2C19

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2C19 P33261 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

3. Cytochrome P450 3A4

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 3A4 P08684 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

4. Cytochrome P450 2C9

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2C9 P11712 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

Transporters

1. Multidrug resistance protein 1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Multidrug resistance protein 1 P08183 Details

References:

  1. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:11